is expected to deliver proof-of-concept clinical data across seven gene therapy and gene editing programs over the next 18 months, with near-term initial proof-of-concept (POC) results in MPS11 and Hemophilia A (both due late summer) up first.
Sangamo ended the quarter with $235 million in cash, not including the $150 million from the KITE/GILD deal or the $215 million from a recent follow-on offering -- together totaling over $600 million.
Year-end 2018 cash guidance of $485 million is sufficient to fund operations for an impressive five years, as the company is building new HQs and manufacturing capacity. More important, Sangamo intends to hold onto and internally develop some longer-term but potentially much larger programs (metabolic diseases, CNS and immunology).
There is a slew of steady progress at Sangamo, creating the leader in the gene therapy, gene editing with by far the most-advanced clinical programs in the field.